Aurobindo Pharma share price
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,610.90.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹90,432 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 24.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 21 May 2026
- 2.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 5 Aug 2026
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 21 May 2026
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,50,60251.3% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 5 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹9,150 Crup 3.35%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1,032 Crup 12.07%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 11.3%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 9 Nov | Dec 2024Filed 6 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 4 Aug | Sep 2025Filed 5 Nov | Dec 2025Filed 9 Feb | Mar 2026Filed 21 May | Jun 2026Filed 5 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 | 8,646 | 8,853 | 9,150 |
| Net profit | 817 | 846 | 903 | 824 | 848 | 910 | 921 | 1,032 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 10.5% | 10.6% | 10.8% | 10.5% | 10.2% | 10.5% | 10.4% | 11.3% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical products, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 87% of 2,480 trading days over the last 10 years.
At or below today's level on 62% of 1,970 trading days since Nov 2018.
At or below today's level on 76% of 1,970 trading days since Nov 2018.
At or below today's level on 7% of 2,480 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +12.7% | +0.9% | +11.4% | 0.3% |
| 3 years | +36.3% | +22.4% | +11.1% | 0.2% |
| 5 years | +8.7% | −7.9% | +17.4% | 0.5% |
Mutual funds holding it
261 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 113 of the 149 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 9
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 5
- AddedAdded. Funds that held more shares than at the end of the month before.
- 79
- CutCut. Funds that held fewer shares than at the end of the month before.
- 70
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 96
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 7
| Fund | |||
|---|---|---|---|
 HDFC Mid Cap FundHDFC Mutual Fund | 1,33,44,745 | 2.19% | ₹2,231.2 Cr |
 quant ELSS Tax Saver Fundquant Mutual Fund | 66,52,259 | 8.49% | ₹1,112.3 Cr |
| quant Mid Cap Fundquant Mutual Fund | 49,02,846 | 10.71% | ₹819.8 Cr |
 SBI Large & Midcap FundSBI Mutual Fund | 47,00,000 | 1.94% | ₹785.8 Cr |
| quant Multi Cap Fundquant Mutual Fund | 42,57,303 | 9.49% | ₹711.8 Cr |
| SBI Flexicap FundSBI Mutual Fund | 40,07,877 | 3.03% | ₹670.1 Cr |
| SBI Midcap FundSBI Mutual Fund | 30,38,512 | 2.18% | ₹508.0 Cr |
| quant Flexi Cap Fundquant Mutual Fund | 30,04,373 | 6.87% | ₹502.3 Cr |
| HDFC Balanced Advantage FundHDFC Mutual Fund | 27,00,437 | 0.44% | ₹451.5 Cr |
| HDFC Large & Mid Cap FundHDFC Mutual Fund | 21,60,032 | 1.27% | ₹361.2 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Aurobindo Pharma in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 CiplaCIPLA | 1,08,093 | 32.1 | 3.1 | 20.2 | +1.8% | −37.5% | 10.3% | 11.6% | 0.97% |
 Laurus LabsLAURUSLABS | 1,06,442 | 97.4 | 20.1 | 53.5 | +22.6% | +114.9% | 22.4% | 19.8% | 0.10% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,02,624 | 31.8 | 2.7 | 20.5 | −0.9% | −43.3% | 9.0% | 6.8% | 0.65% |
 Mankind PharmaMANKIND | 91,390 | 44.6 | 5.6 | 25.4 | +13.8% | +8.2% | 13.4% | 12.8% | 0.00% |
 LupinLUPIN | 88,207 | 16.0 | 3.9 | 9.3 | +28.2% | +49.5% | 27.9% | 28.2% | 0.93% |
 Glenmark PharmaceuticalsGLENMARK | 61,147 | 34.0 | 5.8 | 12.5 | +32.9% | +138.4% | 18.6% | 39.8% | 0.12% |
 Alkem LaboratoriesALKEM | 59,149 | 27.4 | 4.3 | 19.5 | +13.4% | −5.6% | 16.7% | 16.5% | 1.07% |
 Abbott IndiaABBOTINDIA | 53,187 | 32.9 | 11.1 | 25.9 | +6.3% | +11.2% | 35.9% | 39.6% | 2.62% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 8 Aug 2025 | Interim | ₹4.00 |
| 20 Feb 2024 | Interim | ₹1.50 |
| 20 Nov 2023 | Interim | ₹3.00 |
| 17 Feb 2023 | Interim | ₹3.00 |
| 6 Jun 2022 | Interim | ₹4.50 |
| 18 Feb 2022 | Interim | ₹1.50 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
2 Oct · General Updates
2 Oct · Business
1 Oct · Business
Sep 2026
Aurobindo Pharma share price by year
Each calendar year to 2025.Aurobindo Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,183.00 | −11.4% | 1,353.25 | 1,022.20 |
| 2024 | 1,334.50 | +23.1% | 1,569.40 | 990.40 |
| 2023 | 1,084.00 | +147.3% | 1,092.15 | 404.20 |
| 2022 | 438.30 | −40.3% | 737.30 | 437.15 |
| 2021 | 734.35 | −20.3% | 1,047.95 | 627.60 |
| 2020 | 921.30 | +101.7% | 948.85 | 294.70 |
| 2019 | 456.85 | −37.7% | 831.15 | 395.80 |
| 2018 | 732.95 | +6.5% | 823.55 | 533.35 |
| 2017 | 687.95 | +2.8% | 795.90 | 512.40 |
| 2016 | 669.30 | −23.6% | 881.40 | 588.85 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,607.70 | 1,608.80 | 1,547.80 | 1,571.70 | 1,566.81 | 6,50,602 | 51.3% |
| 22 Oct 2026 | 1,570.00 | 1,610.90 | 1,547.70 | 1,610.90 | 1,588.78 | 11,15,532 | 63.3% |
| 21 Oct 2026 | 1,621.40 | 1,636.90 | 1,564.00 | 1,578.80 | 1,585.97 | 12,19,785 | 54.6% |
| 19 Oct 2026 | 1,662.10 | 1,681.60 | 1,615.60 | 1,621.40 | 1,646.27 | 7,36,433 | 52.3% |
| 16 Oct 2026 | 1,677.90 | 1,681.70 | 1,655.00 | 1,666.90 | 1,664.91 | 7,96,734 | 52.9% |
| 15 Oct 2026 | 1,653.20 | 1,684.30 | 1,647.10 | 1,677.90 | 1,672.56 | 7,62,099 | 55.6% |
| 14 Oct 2026 | 1,684.00 | 1,687.70 | 1,654.10 | 1,662.90 | 1,668.03 | 8,99,872 | 57.8% |
| 13 Oct 2026 | 1,706.90 | 1,706.90 | 1,665.50 | 1,684.60 | 1,677.70 | 9,53,166 | 51.7% |
| 12 Oct 2026 | 1,692.50 | 1,715.00 | 1,681.00 | 1,706.90 | 1,699.47 | 11,90,866 | 49.8% |
| 9 Oct 2026 | 1,645.90 | 1,697.90 | 1,633.00 | 1,693.00 | 1,680.18 | 6,99,038 | 42.0% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 20 Jul 2015 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 10 Feb 2011 | Split | 0.2000 | Each share became 5. |
| 8 Oct 2008 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
About Aurobindo Pharma
Aurobindo Pharma Limited develops, manufactures and sells medicines. It is headquartered in Hyderabad, India. Its business spans generic formulations, specialty products and active pharmaceutical ingredients. Finished products are made as oral solids, liquids and injectables. The portfolio covers central nervous system, anti-retroviral, cardiovascular, antibiotic, gastroenterology and anti-diabetic medicines.
Its operations are organised around the US, Europe, Growth Markets, ARV and API businesses, supported by more than 90 subsidiaries. Eugia Pharma Specialities is its specialty pharmaceuticals business, working in oncology and complex injectables. The company also makes dermatology products such as topical products and transdermal patches, and respiratory products such as nasal sprays and inhalation therapies. CuraTeQ Biologics, a wholly-owned subsidiary, develops biosimilars. TheraNym Biologics is its biologics contract manufacturing organisation.
The company has more than 30 manufacturing facilities and 6 R&D centres, and exports to more than 150 countries. In India it runs 16 finished dosage units and 13 API units. Its other sites include a facility at Taizhou in China and a unit in Brazil. More than 20 of its facilities are approved by the US FDA and under EU good manufacturing practice. Its peptide products are made at Auro Peptides.
Part of its growth has come through acquisitions, including Generis and Apotex's businesses. In the year to March 2026, its US subsidiary signed a definitive agreement to acquire Lannett Inc., an Indiana-based manufacturing company focused primarily on controlled substances.
- Legal name
- Aurobindo Pharma Limited
- NSE symbol
- AUROPHARMA
- BSE code
- 524804
- ISIN
- INE406A01037
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Apr 1995 on BSE, Jul 2000 on NSE
- Face value
- ₹1
- CIN
- L24239TG1986PLC015190
- Corporate identity number, the registrar of companies' code for it